Purpose: LUMINOUS is an ongoing 5-year, global, prospective, observational, long-term study being conducted to evaluate the safety and effectiveness of ranibizumab in patients treated according to local product label in routine clinical practice. The aim of the baseline analysis was to evaluate the characteristics of the enrolled patients with respect to the real-world setting.

Methods: 30,000 patients from approximately 500 centres in 34 countries are planned to enrol. Over 8000 patients were recruited in this study by 2012. Baseline (study entry visit) characteristics of cohort I patients recruited from March 2011 to February 2012 are reported here.

Results: Overall, 1915 patients were included in the analysis. Since the majority (n=1877) of these patients had neovascular age-related macular degeneration (nAMD), the following baseline characteristics focus on those patients. Mean age of the patients is 79.2 years, age range is 43 to 100 years, 61.7% are female, and 93.0% are Caucasian. Demographic characteristics such as age, gender and race are well-balanced between treatment-naïve (T1) and treatment non-naïve (T2) groups. 58% of patients are treatment non-naïve; median time since nAMD diagnosis to baseline is 0.9 (T1) and 1.9 (T2) years. Mean visual acuity was 55.8 (T1) and 57.7 (T2) letters and central retinal thickness was 282.8 (T1) and 251.0 (T2) μm. Overall, 31.0% of patients had predominantly classic lesion, 42.0% pigment epithelium detachment, 2.2% polypoidal choroidal vasculopathy and 3.1% retinal angiomatomous proliferation at baseline.

Conclusions: The overall baseline characteristics of the cohort I patients are as expected in the real-world setting.